INVESTOR ALERT: Investigation of Northwest Biotherapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP
July 01 2014 - 05:32PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims on behalf of investors of Northwest
Biotherapeutics, Inc. (“Northwest Biotherapeutics” or the
“Company”) (NASDAQ:NWBO) concerning possible violations of federal
securities laws. The investigation focuses on the Company’s
operations and prospects.
Please contact us at (646) 539-8980, or at
shareholders@glancylaw.com to discuss this matter. If you inquire
by email please include your mailing address, telephone number and
number of shares purchased.
Northwest Biotherapeutics is a biotechnology company engaged in
the discovery and development of immunotherapy products to treat
cancers in the United States and internationally. The Company is
involved in the development of DCVax, a platform technology that
uses activated dendritic cells to mobilize a patient’s own immune
system to attack cancer. The investigation is related to an article
published by TheStreet.com on June 19, 2014, alleging that the MD
Anderson Cancer Center “issued a stern rebuke to Northwest
Biotherapeutics for making promotional, unjustified claims about
results from an ongoing clinical trial of an experimental cancer
vaccine known as DCVax-Direct.” The article further alleges that
the vice president of clinical research at the MD Anderson Cancer
Center stated that claims in certain of the Company’s press
releases concerning the DCVax-Direct clinical trials are
preliminary and unconfirmed. Following this news, the price of
Northwest Biotherapeutics shares dropped nearly 20 percent in
intraday trading on June 19, 2014.
If you purchased Northwest Biotherapeutics securities, if you
have information or would like to learn more about these claims, or
if you have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact
Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 122
East 42nd Street, Suite 2920, New York, NY 10168, at (646)
539-8980, by e-mail to shareholders@glancylaw.com, or visit our
website at http://www.glancylaw.com. If you inquire by email,
please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, New York, NYLesley
Portnoy646-539-8980shareholders@glancylaw.comwww.glancylaw.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2023 to Mar 2024